Royalty Pharma (RPRX) Free Cash Flow (2019 - 2026)

Royalty Pharma has disclosed Free Cash Flow across 8 years of filings, most recently posting $477.4 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 31.57% year-over-year to $477.4 million; the TTM figure through Jun 2026 stood at $577.5 million (down 19.01% YoY), while the FY2025 annual figure was $792.1 million, up 200.85% from the prior year.
• Free Cash Flow came in at $477.4 million for Q2 2026 at Royalty Pharma, up from $265.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $595.0 million in Q1 2025 to a low of -$777.5 million in Q3 2022.
• Average Free Cash Flow over 5 years is $170.7 million, with a median of $292.8 million recorded in 2022.
• Year-over-year, Free Cash Flow surged 1898.2% in 2022 and plunged 501.15% in 2024.
• Over 5 years, Free Cash Flow stood at $319.7 million in 2022, then sank by 171.82% to -$229.6 million in 2023, then soared by 207.18% to $246.1 million in 2024, then tumbled by 62.02% to $93.5 million in 2025, then jumped by 410.83% to $477.4 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $477.4 million in Q2 2026, $265.9 million in Q1 2026, and $93.5 million in Q4 2025.